Flower Hospital

The trials here

What the 11 trials at this site are about, from their registry records.

Conditions

• Lung cancer2 trials
• Multiple myeloma2 trials
• Prostate cancer2 trials
• Cervical cancer1 trial
• Childhood cancers1 trial
• Head and neck cancer1 trial
• Kidney cancer1 trial
• Ovarian cancer1 trial
• Pancreatic cancer1 trial

Phase

• Phase 38 trials
• Phase 1/21 trial
• Phase 21 trial
• Phase 2/31 trial

Status

• Completed8 trials
• Active, not recruiting3 trials

Lead sponsor

• Radiation Therapy Oncology Group4 trials
• SWOG Cancer Research Network4 trials
• ECOG-ACRIN Cancer Research Group2 trials
• ETOP IBCSG Partners Foundation1 trial

Running trials

• Active, not recruiting

  Lung-MAP: Nivolumab With or Without Ipilimumab as Second-Line Therapy in Treating Patients With Recurrent Stage IV Squamous Cell Lung Cancer and No Matching Biomarkers

  NCT02785952· Phase 3· SWOG Cancer Research Network· Source

• Active, not recruiting

  Bortezomib or Carfilzomib With Lenalidomide and Dexamethasone in Treating Patients With Newly Diagnosed Multiple Myeloma

  NCT01863550· Phase 3· ECOG-ACRIN Cancer Research Group· Source

• Active, not recruiting

  RT With or Without Cetuximab in Treating Patients Who Have Undergone Surgery for Locally Advanced Head and Neck Cancer

  NCT00956007· Phase 3· Radiation Therapy Oncology Group· Source

Closed trials

• Completed

  S1403, Afatinib Dimaleate With or Without Cetuximab in Treating Patients With Newly Diagnosed Stage IV or Recurrent, EGFR Mutation Positive Non-small Cell Lung Cancer

  NCT02438722· Phase 2/3· SWOG Cancer Research Network· Source

• Completed

  Temozolomide With or Without Capecitabine in Treating Patients With Advanced Pancreatic Neuroendocrine Tumors

  NCT01824875· Phase 2· ECOG-ACRIN Cancer Research Group· Source

• Completed

  S1211 Bortezomib, Dexamethasone, and Lenalidomide With or Without Elotuzumab in Treating Patients With Newly Diagnosed High-Risk Multiple Myeloma

  NCT01668719· Phase 1/2· SWOG Cancer Research Network· Source

• Completed

  Hormone Therapy, Radiation Therapy, and Steroid 17alpha-monooxygenase TAK-700 in Treating Patients With High-Risk Prostate Cancer

  NCT01546987· Phase 3· Radiation Therapy Oncology Group· Source

• Completed

  S0931, Everolimus in Treating Patients With Kidney Cancer Who Have Undergone Surgery

  NCT01120249· Phase 3· SWOG Cancer Research Network· Source

• Completed

  Radiation Therapy With or Without Androgen-Deprivation Therapy in Treating Patients With Prostate Cancer

  NCT00936390· Phase 3· Radiation Therapy Oncology Group· Source

• Completed

  Chemotherapy and Pelvic Radiation Therapy With or Without Additional Chemotherapy in Treating Patients With High-Risk Early-Stage Cervical Cancer After Radical Hysterectomy

  NCT00980954· Phase 3· Radiation Therapy Oncology Group· Source

• Completed

  Suppression of Ovarian Function With Either Tamoxifen or Exemestane Compared With Tamoxifen Alone in Treating Premenopausal Women With Hormone-Responsive Breast Cancer

  NCT00066690· Phase 3· ETOP IBCSG Partners Foundation· Source